Morten Daniel Jensen

Morten Daniel Jensen

Auto-generated profile, based on publicly available information

Morten Daniel Jensen

Department of Hepatology and Gastroenterology Aarhus University Hospital Aarhus Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2021 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
MJMorten D. Jensen
Morten D. Jensen
PJPeter Jepsen
Peter Jepsen
HVHendrik Vilstrup
Hendrik Vilstrup
LGLisbet Grønbæk
Lisbet Grønbæk
INTRODUCTION: Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease and as such may increase the risk of cancer. We examined cancer risks in a nationwide cohort of patients with AIH. METHODS: This study was based on nationwide Danish healthcare registries. We identified all persons diagnosed with AIH between 1994 and 2018. We included 1805 patients with AIH and 16,617 age- and sex-matched population controls. We estimated cumulative risks of cancers and risk ratios (RRs) between patients and controls. Within the cohort of patients with AIH, we examined the impact of immunosuppressive treatment (IST) and cirrhosis on cancer risks. RESULTS: The 10-year risk of any cancer was 13.6% (95% confidence interval [CI] 11.7–15.6) in patients with AIH with an RR of 1.5 (95% CI 1.3–1.7) compared with controls. Patients with AIH had a 10-year risk of 0.5% (95% CI 0.2–1.1) for hepatocellular carcinoma. The 10-year risk was 1.6% (95% CI 1.0–2.5) for colorectal cancer (RR: 2.1 [95% CI 1.3–3.5]) and 4.0% (95% CI 3.0–5.3) for nonmelanoma skin cancer (RR: 1.8 [95% CI 1.3–2.5]). Among patients with AIH, the risk of cancer was higher for those with cirrhosis (hazard ratio: 1.3 [95% CI 1.0–1.7]), and it also increased 1.05-fold (95% CI 1.0–1.1) for every year the patient was on IST. DISCUSSION: AIH was associated with a 1.5-fold increased 10-year risk of cancer compared with age- and sex-matched controls. Among patients with AIH, the risk of cancer was higher for those with cirrhosis, and it also increased slightly with longer duration of IST.

1 February 2024 in American Journal of Gastroenterology
Verified
Journal Article
Open access
GAGro Askgaard
Gro Askgaard
PJPeter Jepsen
Peter Jepsen
MJMorten Daniel Jensen
Morten Daniel Jensen
AKAnna Emilie Kann
Anna Emilie Kann
JMJoanne Morling
Joanne Morling
JWJoe West
Joe West
INTRODUCTION: England has seen an increase in deaths due to alcohol-related liver disease (ALD) since 2001. We studied the influence of socioeconomic position on the incidence of ALD and the mortality after ALD diagnosis in England in 2001–2018. METHODS: This was an observational cohort study based on health records contained within the UK Clinical Practice Research Datalink covering primary care, secondary care, cause of death registration, and deprivation of neighborhood areas in 18.8 million residents. We estimated incidence rate and incidence rate ratios of ALD and hazard ratios of mortality. RESULTS: ALD was diagnosed in 57,784 individuals with a median age of 54 years and of whom 43% had cirrhosis. The ALD incidence rate increased by 65% between 2001 and 2018 in England to reach 56.1 per 100,000 person-years in 2018. The ALD incidence was 3-fold higher in those from the most deprived quintile vs those from the least deprived quintile (incidence rate ratio 3.30, 95% confidence interval 3.21–3.38), with reducing inequality at older than at younger ages. For 55- to 74-year-olds, there was a notable increase in the incidence rate between 2001 and 2018, from 96.1 to 158 per 100,000 person-years in the most deprived quintile and from 32.5 to 70.0 in the least deprived quintile. After ALD diagnosis, the mortality risk was higher for patients from the most deprived quintile vs those from the least deprived quintile (hazard ratio 1.22, 95% confidence interval 1.18–1.27), and this ratio did not change during 2001–2018. DISCUSSION: The increasing ALD incidence in England is a greater burden on individuals of low economic position compared with that on those of high socioeconomic position. This finding highlights ALD as a contributor to inequality in health.

18 August 2022 in Liver International
Verified
Journal Article
Open access
RBRasmine Birn‐Rydder
Rasmine Birn‐Rydder
MJMorten D. Jensen
Morten D. Jensen
PJPeter Jepsen
Peter Jepsen
LGLisbet Grønbæk
Lisbet Grønbæk
Background and Aims: Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease associated with an increased prevalence of extrahepatic autoimmune diseases and an increased mortality compared with the general population. The contribution of extrahepatic autoimmune diseases to the increased mortality has not been clarified. Our aim was to determine the effect of extrahepatic autoimmune diseases on mortality in AIH patients.Methods: This nationwide register‐based cohort study included all Danish patients diagnosed with AIH between 1995 and 2019. We examined the presence of extrahepatic autoimmune diseases and compared the mortality between AIH patients with and without extrahepatic autoimmune diseases. We adjusted our analysis for age, sex, calendar year of AIH diagnosis, cirrhosis, cancer, chronic obstructive pulmonary disease and ischaemic heart disease.Results: We included 2479 AIH patients of whom 19.8% had one extrahepatic autoimmune disease and 3.3% had multiple. The adjusted 10‐year cumulative mortality was 27.2% (95% confidence interval [CI]: 25.2–29.4) for patients with extrahepatic autoimmune diseases and 21.6% (95% CI: 19.9–23.6) for patients without. The adjusted mortality hazard ratio was 1.30 (95% CI: 1.12–1.52) for AIH patients with versus without extrahepatic autoimmune diseases; it was 1.25 (95% CI: 1.06–1.48) for patients with one extrahepatic autoimmune disease and 1.54 (95% CI: 1.15–2.05) for those with more than one.Conclusions: Extrahepatic autoimmune diseases increased the mortality in patients with AIH. Patients with multiple extrahepatic autoimmune diseases had a higher mortality than patients with just one extrahepatic autoimmune disease.

1 March 2020 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
MJMorten Daniel Jensen
Morten Daniel Jensen
TLTorsten Lauritzen
Torsten Lauritzen
HVHendrik Vilstrup
Hendrik Vilstrup
PJPeter Jepsen
Peter Jepsen
Purpose: Alanine aminotransferase is the most frequently used marker of liver cell injury. We examined the association between alanine aminotransferase levels and long-term absolute risks of morbidity and mortality in healthy Danish people aged 30– 49 years. Patients and Methods: We divided 671 healthy participants from the Ebeltoft Health Promotion Project into four categories based on their baseline alanine aminotransferase values: low (≤ 10U/l), medium-low (men: 11– 34U/l, women: 11– 22U/l), medium-high (men: 35– 69U/l, women: 23– 44U/l) and high (men: ≥ 70U/l, women: ≥ 45U/l), and followed them through Danish healthcare registries for up to 20 years. We examined mortality and absolute risks of liver disease, overall cancer, ischemic heart disease, and diabetes. Results: The risk of any cancer was highest for participants with “low alanine aminotransferase” or “high alanine aminotransferase” (20-year risk: 17.2% [95% confidence interval (CI): 6.3– 32.7%] and 18.2% [95% CI: 5.7– 36.3%], respectively). The risk of diabetes was highest for participants with “medium-high alanine aminotransferase” or “high alanine aminotransferase” (20-year risk: 12.1% [95% CI: 7.3– 18.3%] and 9.1% [95% CI: 1.6– 25.1%], respectively). Participants with “high alanine aminotransferase” had the highest 20-year risk of liver disease (20-year risk: 13.6% [95% CI: 3.4– 30.9%], while it was 1.0% or less in the other groups). The chance of being alive after 20 years without having been diagnosed with liver disease, cancer, ischemic heart disease, or diabetes was lowest in the “high alanine aminotransferase” group (50% [95% CI: 28– 68%]) and 72– 79% in the other groups. Conclusion: Our findings suggest that persons with high or abnormally low alanine aminotransferase measurements are at increased long-term risk of several chronic diseases.

9 September 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
MJMorten Daniel Jensen
Morten Daniel Jensen
JWJoe West
Joe West
CCColin Crooks
Colin Crooks
JMJoanne R. Morling
Joanne R. Morling
FKFrederik Kraglund
Frederik Kraglund
PJPeter Jepsen
Peter Jepsen
INTRODUCTION: Patients with alcohol-related cirrhosis (ALD cirrhosis) have an increased risk of primary liver cancer (hepatocellular carcinoma [HCC] or intrahepatic cholangiocarcinoma [iCCA]). England recommends surveillance for HCC in these patients, while Denmark does not. METHODS: We performed an observational cohort study using the English Clinical Practice Research Datalink and the nationwide Danish healthcare registries to identify 17,110 English (2000–2016) and 22,122 Danish (1994–2022) patients with diagnosis codes of ALD cirrhosis. We computed and compared incidence rates and cumulative incidence of primary liver cancer, annual ultrasound scan rates, and mortality following diagnosis of primary liver cancer. RESULTS: The overall risk of primary liver cancer was similar in England and Denmark: 5-year risk was 2.24% (95% confidence interval 2.00–2.49) in England (iCCA 0.07%, HCC 2.16%) and 2.36% (2.15–2.57) in Denmark (iCCA 0.05%, HCC 2.30%). The annual rate of ultrasound scans per person was 0.65 (0.63–0.67) in England and 0.44 (0.42–0.46) in Denmark. The 1-year mortality after a diagnosis of primary liver cancer was 59.2% (54.4–64.0) in England and 60.9% (57.4–64.4) in Denmark. The 3-year risks of HCC in those on vs off surveillance in England were 2.3% (1.0–4.6) vs 1.5% (1.0–2.2). DISCUSSION: The risk of primary liver cancer was the same in English and Danish patients with ALD cirrhosis, and HCCs constituted 97% of primary liver cancers. Mortality with primary liver cancer was equally high in both countries. Notably, in England, where guidance recommends biannual HCC surveillance with ultrasound, patients with ALD cirrhosis were undergoing fewer than 1 ultrasound scan per year.

1 June 2023 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
MJMorten Daniel Jensen
Morten Daniel Jensen
HWHugh Robert WATSON
Hugh Robert WATSON
HVHendrik Vilstrup
Hendrik Vilstrup
PJPeter Jepsen
Peter Jepsen
Background and Aims: Previous studies have not been able to determine whether non-selective beta-blockers (NSBB) reduce the risk of sepsis in cirrhosis. We aimed to examine this question with data from 1198 patients with cirrhosis and ascites included in clinical studies of satavaptan, a vasopressin receptor antagonist with no effect on infection risk. Methods: Risk of sepsis was estimated for NSBB users vs nonusers. Patients were examined every four weeks, or in relation to hospitalization, for the one-year duration of the trials. We computed the cumulative risk of sepsis for patients who did vs did not use NSBB at baseline. We used Cox regression to compare hazard rates of sepsis between current users and nonusers, accounting for changes in NSBB use over time. We adjusted for patient sex and age, MELD-Na score, albumin, use of antibiotics, use of proton pump inhibitors, cirrhosis etiology, history of variceal bleeding or SBP, severity of ascites and HE, HCC, other cancers, and diabetes, while stratifying on geographical region. Results: Of the 1198 patients, 54% used NSBB at some time. There were 56 sepsis episodes. The 1-year risk of sepsis was reduced to 5.7% (95% confidence interval [CI] 2.8– 8.6) in baseline NSBB users vs 11.6% (95% CI 7.0– 15.9) in baseline nonusers. The hazard ratio of sepsis for current NSBB users vs current nonusers was reduced to 0.5 (95% CI 0.3– 0.8) and after adjustment to 0.7 (95% CI 0.4– 1.3). Conclusion: NSBB use may reduce the risk of sepsis in patients with cirrhosis and ascites, but the precision of the estimate was limited by the number of episodes of sepsis.